Higher Carbohydrate Antigen 125 Levels Are Associated with Increased Risk of Coronary Heart Disease in Elderly Chinese: A Population-Based Case-Control Study

Citation
Li, X., M. He, J. Zhu, P. Yao, X. Li, J. Yuan, X. Min, et al. 2013. “Higher Carbohydrate Antigen 125 Levels Are Associated with Increased Risk of Coronary Heart Disease in Elderly Chinese: A Population-Based Case-Control Study.” PLoS ONE 8 (11): e81328. doi:10.1371/journal.pone.0081328. http://dx.doi.org/10.1371/journal.pone.0081328.

Published Version
doi:10.1371/journal.pone.0081328

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879251

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Higher Carbohydrate Antigen 125 Levels Are Associated with Increased Risk of Coronary Heart Disease in Elderly Chinese: A Population-Based Case-Control Study

Xiaorong Li¹,², Meian He², Jiang Zhu³, Ping Yao², Xiulou Li³, Jing Yuan², Xinwen Min³, Mingjian Lang³, Handong Yang³, Frank B. Hu⁴, Tangchun Wu², Sheng Wei¹,2*

¹ Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ² MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China, ³ Dongfeng Central Hospital, Dongfeng Motor Corporation and Hubei University of Medicine, Shiyan, Hubei, China, ⁴ Departments of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America

Abstract

Background: High carbohydrate antigen 125 (CA-125) level was reported to be associated with some cardiac dysfunctions, such as chronic heart failure, but the relationship between CA-125 level and coronary heart disease (CHD) risk remains unclear. The aim of this study was to explore the potential association in a Chinese older population.

Methods: In a population-based case-control study conducted in a Chinese older population, serum CA-125 levels were measured in 1177 diagnosed CHD patients and 3531 age and sex matched control subjects without CHD.

Results: Serum CA-125 level was significantly higher in CHD patients than controls (P < 0.001) with adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction. CHD risk was doubled (OR: 2.10, 95%CI: 1.69-2.60) among subjects in the highest quartile compared to those in the lowest quartile of CA-125 level (P_trend < 0.001). Furthermore, CA-125 levels were associated with CHD risks in subjects with age over 60 years (OR: 2.19, 95%CI: 1.75-2.73), current smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR: 2.35, 95%CI: 1.57-3.53) and subjects with hypertension (OR: 2.04, 95%CI: 1.71-2.43).

Conclusions: Elevated serum CA-125 level might be associated with increased risk of coronary heart disease in the Chinese older population. Further investigations are needed to identify the possible biological role of CA-125 in CHD development in the future.

Introduction

CA-125 (Carbohydrate antigen 125) is a well-established tumor marker to monitor the efficacy of ovarian cancer therapy and early detect its recurrence [1]. But it is also elevated in both ovarian and non-ovarian diseases, malignant and non-malignant conditions [2]. Interestingly, there are evidences which showed that, CA-125 could be secreted from mesothelial cells as well as tumoural origin tissue [3,4]. Recent studies have also demonstrated that serum CA-125 level was significantly elevated in chronic heart failure patients [5-9]. Furthermore, increasing evidences have indicated that high serum CA-125 levels were associated with risk of hypertrophic cardiomyopathy, pseudoaneurysm of the left ventricular lateral wall, cardiac angiosarcoma, pericardial tamponade, infective perimyocarditis and atrial fibrillation [10-15]. However, few studies have investigated whether the higher concentration of serum CA-125 is associated with the increased risk of coronary heart disease (CHD) or not until now.
Coronary heart disease (CHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there is an imbalance between myocardial oxygen supply and demand. It is one of the leading causes of mortality and disability in both industrialized and developing countries [16-18]. It was estimated that heart disease and stroke are projected to be the single leading cause of death by 2030 [19]. CHD is a multifactorial disease and the underlying mechanisms of CHD have not been well elucidated clearly. Inflammation is considered to play an important role in the development of atherosclerosis [20,21]. Systemic inflammation could enhance atherogenesis and inflammatory components could drive the formation, progression and rupture of atherosclerotic plaques for inflammation could promote loss of endothelium, the hallmark of superficial erosion [22-25]. Previous studies have also found that CA-125 could be produced by mesothelial cells as a consequence of inflammation, stasis or other stimulatory mechanisms in patients with heart failure [5,6,9,26]. Recently, a small case-control study also suggested inflammation and cytokine levels may be responsible for CA-125 production and release [27]. Given this evidence, it is reasonable to hypothesize that there may be a potential association between serum CA-125 level and CHD risk.

Here, we performed a large population-based case-control study to explore the association between serum CA-125 level and the CHD risk in Chinese older population, which was based on Dongfeng-Tongji cohort study of retired workers in Shiyan, Hubei province, China.

Methods

Ethics statement

Ethical approval was obtained from the Medical Ethics Committee of the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology.

Study population and design

We used data from Dongfeng-Tongji cohort (DFTJ cohort) study of retired workers, which was described in detail elsewhere [28]. Briefly, this cohort was launched in 2008 among retirees of Dongfeng Motor Corporation (DMC) in Shiyan City, Hubei province, China. For the current study, we included 1177 documented CHD cases and 3531 frequency-matched (by age and gender) controls between September 2008 and June 2010. CHD was confirmed on the basis of the most recent international guidelines: a combination of classical symptoms with positive results from 12-lead electrocardiograph (ECG), cardiac enzymes, functional or stress test, or coronary angiography using standard Judkins techniques (significant coronary artery stenosis≥50% in at least one major coronary artery) [29]. A total of 55.73% (656) CHD cases underwent coronary angiography. Nonfatal myocardial infarction was diagnosed by a development of pathologic Q waves on serial ECG, elevations of cardiac enzyme values, or medical records for clinical symptoms and signs. 210 of CHD cases were diagnosed as MI according to their medical record.

Controls were randomly selected from retired employees employed in the same DFTJ cohort on the basis of medical history, clinical examinations, electrocardiography and face-to-face inquiry at admission. None of them had abnormalities of ECG or diagnostic evidence of CHD. Hypertension was defined as systolic/ diastolic blood pressure≥140/90mmHg in at least two measurements, or current use of anti-hypertensive medicine for the most recent 2 weeks, or a previous diagnosis of hypertension by a clinician. Diabetes mellitus (DM) was defined by the WHO criteria [30]: fasting blood glucose (FBG) ≥7mmol/L or a 2 hour postprandial plasma glucose ≥11.1mmol/L, or a prescription history of antidiabetic medications, including oral antidiabetics, incretin products, and insulin during the most previous two weeks, or a previous diagnosis of DM. Dyslipidemia was diagnosed as total cholesterol (TC) concentration≥5.72 mmol/L or triglyceride (TG) concentration ≥1.70 mmol/L or high-density lipoprotein cholesterol (HDL-C) concentrations<0.91mmol/L, or use medicine of dyslipidemia during the previous two weeks, or a positive history for dyslipidemia. All chronic diseases were verified through medical record reviews.

Subjects with a history of congenital heart disease, chronic heart failure, recent acute coronary syndrome (< 6 months), vascular disease, valvular disease, cardiomyopathy and neoplastic diseases and cancers were excluded through medical record review based on clinical symptoms, physical examination, electrocardiogram and chest X-ray.

After obtained written informed consent from every participant, a semi-structural questionnaire was used to collect baseline information by trained interviewers during face-to-face interviews. The medical examination was performed at the same time. Demographic information, socio-economic status, family and personal disease histories, medication history in recent two weeks, alcohol use and smoking consumption were also inquired in the questionnaire.

Educational levels were categorized as low (primary school or illiteracy), medium (junior high school) and high (senior high school, university or college or higher). Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

Laboratory measurement

After an overnight fast, five milliliters of fasting blood was drawn from all subjects with a vacuum coagulation tube for serum in the morning. We measured the serum CA-125 level with the ARCHITECT Ci8200 automatic analyzer (ABBOTT Laboratories. Abbott Park, Illinois, U.S.A.) using the Abbott Diagnostics reagents according to the manufacturer’s instructions at Dongfeng Central Hospital’s laboratory. The method used by the ARCHITECT Ci8200 platform for serum CA-125 levels measurement is microparticle chemiluminescent immunoassay (CMIA).The intra-assay coefficients of variation were 5.50% for CA-125. Blood glucose and blood lipids (including TC, TG and HDL-C) measurements were described in our previous study [28].

November 2013 | Volume 8 | Issue 11 | e81328
Statistical analysis

Characteristics of study subjects are presented as mean (SD) for continuous variables and as percentages for categorical data. All continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. For serum CA-125 levels, the cut off values for division of data into concentration categories were based on the distribution in controls. Continuous variables were analyzed by 2-tailed t tests for normal distributions and the Mann-Whitney U test for nonparametric distributions. Categorical data were evaluated by Chi-square test as appropriate. Odds ratios and 95% confidence intervals were estimated by logistic regression with and without adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction. All tests were two-sided and α < 0.05 was considered statistically significant. Analyses were performed using SPSS software (version 12.0; SPSS Inc., Chicago, IL, USA).

Results

Characteristics of study population

The demographic characteristics of the study population are presented in Table 1. When compared with the controls, smoking (P < 0.001) and higher BMI (P < 0.001) were more common in cases while lower DBP (P < 0.001) and less drinking (P < 0.001) were found among cases. Total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) were lower in CHD cases than controls (P < 0.001). As expected, CHD patients were more likely to have hypertension, dyslipidemia and diabetes mellitus (P < 0.001, respectively). Pharmacological drugs (antibiotics, anticoagulant, anti-hypertensive and hypoglycemic drugs) were more often used in cases (P < 0.001, respectively). Median and range of CA-125 level were 7.60 U/ml (3.50-11.40 U/ml) in cases and 5.54 U/ml (1.31-9.90 U/ml) in controls. Serum CA-125 level was significantly higher in CHD cases than that in controls (P < 0.001).

Table 1. Demographic characteristics of study subjects.

| Demographic and risk factors | Cases (n = 1177) | Controls (n = 3531) | P-value |
|-----------------------------|-----------------|---------------------|---------|
| Age                         |                 |                     | 0.995   |
| < 60                        | 106 (9.01)      | 319 (9.03)          |         |
| 60-                         | 566 (48.09)     | 1703 (48.23)        |         |
| ≥ 70                        | 505 (42.91)     | 1509 (42.74)        |         |
| Gender                      |                 |                     | 0.93    |
| Male                        | 616 (52.34)     | 1853 (52.48)        |         |
| Female                      | 561 (47.66)     | 1678 (47.52)        |         |
| Education levels†           |                 |                     | 0.65    |
| Low                         | 395 (33.85)     | 1149 (32.79)        |         |
| Medium                      | 402 (34.45)     | 1194 (34.08)        |         |
| High                        | 370 (31.71)     | 1161 (33.13)        |         |
| BMI (kg / m²)               |                 |                     | < 0.001 |
| < 23.9                      | 371 (32.04)     | 1605 (46.44)        |         |
| 24-                         | 552 (47.67)     | 1387 (40.13)        |         |
| ≥ 28                        | 235 (20.29)     | 464 (13.43)         |         |
| Physical activity           | 1043 (88.62)    | 3198 (90.57)        | 0.052   |
| Blood pressure (mmHg)       |                 |                     |         |
| SBP                         | 131.91 ± 17.36  | 131.29 ± 18.25      | 0.31    |
| DBP                         | 76.15 ± 10.47   | 77.35 ± 10.47       | 0.001   |
| TC (mmol/L)                 | 4.89 ± 1.14     | 5.21 ± 0.97         | < 0.001 |
| TG (mmol/L)                 | 1.49 ± 0.95     | 1.43 ± 1.05         | 0.12    |
| HDL (mmol/L)                | 1.34 ± 0.36     | 1.44 ± 0.41         | < 0.001 |
| Smoking status              |                 |                     |         |
| Current                     | 148 (12.60)     | 693 (19.73)         |         |
| Former                      | 277 (23.57)     | 415 (11.81)         |         |
| Never                       | 750 (63.83)     | 2405 (68.46)        |         |
| Drinking status             |                 |                     | < 0.001 |
| Current                     | 170 (14.46)     | 788 (22.32)         |         |
| Former                      | 133 (11.31)     | 159 (4.50)          |         |
| Never                       | 873 (74.23)     | 2583 (73.17)        |         |
| Medication history          |                 |                     |         |
| Antibiotics                 | 114 (9.69)      | 177 (5.01)          | < 0.001 |
| Anticoagulant               | 682 (57.94)     | 359 (10.17)         | < 0.001 |
| Anti-hypertensive medication| 770 (65.42)     | 965 (27.33)         | < 0.001 |
| Hypoglycemic medication     | 257 (21.84)     | 346 (9.80)          | < 0.001 |
| Disease History             |                 |                     |         |
| Hypertension                | 942 (80.03)     | 1919 (54.35)        | < 0.001 |
| Diabetes mellitus           | 371 (31.52)     | 664 (18.90)         | < 0.001 |
| Dyslipidemia                | 905 (76.89)     | 1932 (54.72)        | < 0.001 |
| Family history of disease   |                 |                     |         |
| Coronary heart disease      | 183 (15.55)     | 186 (5.27)          | < 0.001 |
| Myocardial infarction       | 30 (2.62)       | 32 (0.92)           | < 0.001 |

| CA-125 level (U/ml)         |                 |                     | < 0.001* |
| 7.60 (3.50-11.40)           | 5.54 (1.31-9.90) |                     |         |

Data are presented as number (percentage) or mean ± SD unless noted otherwise. CA-125 is presented as median (25th-75th quartile). P values were calculated using 2-tailed t tests or Chi-square test.

P value was obtained using the Mann-Whitney U test.

Education levels†: Low, Primary school or illiteracy; Medium, Junior high school; High, Senior high school, university or college or higher.

Abbreviations: TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein.

doi: 10.1371/journal.pone.0081328

The CHD risk was inclined to be stronger among current smokers (OR: 2.29, 95%CI: 1.50-3.49), current drinkers (OR:
among controls

Relation of CHD risk factors and serum CA-125 level among controls

Serum CA-125 level of controls ascended substantially with increasing age ($P_{\text{trend}} < 0.001$; Table 4). Males tended to have higher serum CA-125 level than females ($P = 0.015$). Smokers had significantly higher CA-125 level than nonsmokers ($P = 0.04$). Controls with hypertension have significantly lower serum CA-125 level than those without hypertension ($P = 0.001$). Contrary results were found in controls with and without diabetes mellitus ($P < 0.001$). Controls taken hypoglycemic drugs tend to have significantly higher level of CA-125 ($P = 0.03$).

Table 2. The association between CA-125 level and CHD risk in Chinese older population.

| CA-125 level (U/ml) | Cases, n (%) | Controls, n (%) | OR (95% CI) | OR² (95% CI) |
|---------------------|--------------|-----------------|-------------|--------------|
| First ≤ 1.31        | 191 (16.23)  | 881 (24.95)     | 1.00        | 1.00         |
| Second 1.31-5.54    | 215 (18.27)  | 884 (25.04)     | 1.12        | 1.11         |
| Third 5.54-9.90     | 380 (32.29)  | 877 (24.84)     | 2.00        | 2.08         |
| Fourth ≥ 9.90       | 391 (33.22)  | 889 (25.18)     | 2.03        | 2.10         |

CA-125 levels and the severity of coronary artery stenoses in CHD

We divided the 1177 CHD cases into two groups: CHD accompanying with MI (210, Table S1) and CHD without MI (967, Table S2), and then compared the two groups with controls (3531) respectively, the adjusted OR of CHD patients accompanying with MI in highest quartile of CA-125 level was 2.76 (95% CI: 1.73-4.41, $P < 0.001$), and that of CHD patients without MI was 2.02 (95% CI: 1.61-2.54, $P < 0.001$) after adjustment for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction.

Relation of CHD risk factors and serum CA-125 level by subgroups.

Table 3. Associations between CA-125 level and CHD risk by subgroups.

| Risk factors | Level | Cases, n (%) | Controls, n (%) | OR (95% CI) | OR² (95% CI) |
|-------------|-------|--------------|-----------------|-------------|--------------|

Age

- < 60
  - Low: 51, 163
  - High: 55, 156
  - OR: 1.12 (1.09-1.15), $P = 0.02$
  - OR²: 1.12 (1.09-1.15), $P = 0.02$

- ≥ 70
  - Low: 154, 707
  - High: 351, 802
  - OR: 2.01 (1.92-2.10)
  - OR²: 2.01 (1.92-2.10)

Gender

- Male
  - Low: 198, 898
  - High: 418, 955
  - OR: 1.00
  - OR²: 1.00

- Female
  - Low: 353, 811
  - High: 1.94 (1.04-3.67)
  - OR²: 1.94 (1.04-3.67)

BMI

- < 23.9
  - Low: 127, 807
  - High: 244, 798
  - OR: 2.00 (1.55-2.58)
  - OR²: 2.00 (1.55-2.58)

- ≥ 28
  - Low: 87, 246
  - High: 156, 245
  - OR: 1.80 (1.31-2.47)
  - OR²: 1.80 (1.31-2.47)

Smoking status

- Current
  - Low: 50, 360
  - High: 32, 212
  - OR: 2.92 (1.50-5.72)
  - OR²: 2.92 (1.50-5.72)

- Former
  - Low: 90, 188
  - High: 227, 172
  - OR: 1.93 (1.54-2.44)
  - OR²: 1.93 (1.54-2.44)

- Never
  - Low: 82, 96
  - High: 156, 245
  - OR: 1.91 (1.56-2.35)
  - OR²: 1.91 (1.56-2.35)

Drinking status

- Current
  - Low: 49, 399
  - High: 389, 253
  - OR: 2.35 (1.57-3.53)
  - OR²: 2.35 (1.57-3.53)

- Former
  - Low: 51, 63
  - High: 96, 106
  - OR: 2.13 (1.29-3.44)
  - OR²: 2.13 (1.29-3.44)

- Never
  - Low: 305, 1303
  - High: 568, 1280
  - OR: 2.05 (1.72-2.45)
  - OR²: 2.05 (1.72-2.45)

Disease history

- Hypertension
  - Yes
    - Low: 330, 1009
    - High: 612, 910
    - OR: 2.06 (1.75-2.42)
    - OR²: 2.06 (1.75-2.42)

- No
  - Low: 76, 756
  - High: 159, 856
  - OR: 1.85 (1.38-2.47)
  - OR²: 1.85 (1.38-2.47)

- Dyslipidemia
  - Yes
    - Low: 314, 958
    - High: 591, 974
    - OR: 1.85 (1.57-2.18)
    - OR²: 1.85 (1.57-2.18)

- No
  - Low: 92, 807
  - High: 283, 1481
  - OR: 1.99 (1.52-2.61)
  - OR²: 1.99 (1.52-2.61)

- Diabetes mellitus
  - Yes
    - Low: 123, 284
    - High: 248, 380
    - OR: 1.51 (1.16-1.97)
    - OR²: 1.51 (1.16-1.97)

- No
  - Low: 283, 1481
  - High: 523, 1386
  - OR: 1.98 (1.68-2.32)
  - OR²: 1.98 (1.68-2.32)
Table 3 (continued).

Low*: the first and second quartiles; High: the third and fourth quartiles.
OR#: Adjusted for age, gender, smoking, drinking, BMI, physical activity, hypertension, dyslipidemia, diabetes mellitus, medication history and family history of CHD and myocardial infarction.
doi: 10.1371/journal.pone.0081328.t003

Discussion

In this population-based case-control study, we investigated the association between serum CA-125 level and the risk of CHD in a large Chinese older population for the first time. We observed that the elevated serum CA-125 level was associated with a higher risk of CHD, and such associations were also evident in older individuals, males, current smokers and drinkers, overweight individuals, and those who had hypertension.

In early time, serum CA-125 was found to be related to diastolic and systolic parameters, ejection fraction and myocardial performance index in patients with chronic HF [31]. Subsequently, elevated CA-125 level has also been observed in other cardiac pathologies such as aortic stenosis, mitral stenosis, mitral valve endocarditis, acute myocardial infarction [32-36]. However, in stark contrast, little data has been published concerning the association of the concentration of serum CA-125 and CHD risk until now.

As to the possible mechanisms involved in increased CA-125 level observed in HF, De Gennaro et al. suggested that haemodynamic abnormalities and inflammatory cytokines may play significant roles in the development of atherosclerosis and its complications [37]. A few later studies have also demonstrated that CA-125 is expressed in different tissues derived from coelomic epithelium in response to various stimuli, including mechanical stress and inflammatory stimuli [38-41]. Furthermore, under normal circumstances, mesothelial cells could maintain a steady-state with proliferation balanced by cell death. However, such balance is disrupted when mesothelial cells are exposed to mechanical stress and inflammatory stimuli in the early phase of atherosclerosis. On the one hand, mesothelial cells might synthesize more hyaluronan and cytoplasmic fibers to defense the cellular injury and death [42,43]. Vitro experiments have demonstrated that the secretion of CA-125 could be enhanced by the inflammatory cytokines [44]. So inflammatory may be responsible for serum CA-125 role in CHD development. Our findings suggested that serum CA-125 was related to some inflammatory related status, such as smoking, hypertension and diabetes mellitus, may act as an evidence to support this hypothesis.

In our study, CA-125 level-associated CHD risks were higher in subjects aged over 60 years, overweight individuals, cigarette smoke and hypertension. The similar results have been found in the PLCO (Prostate, Lung, Colorectal and Ovarian Cancer) screening trial [45] except for subjects with hypertension. These factors may damage the endothelium and lead to the subsequent inflammatory reactions in the vascular wall, which in turn increases the production of primary proinflammatory cytokines [46]. The association of higher CA-125 level with higher CHD risk in older age could possibly be a consequence of aging processes at the cellular and immunological level [45]. Cigarette smoke is a major risk factor for CHD and produces a chronic inflammatory state that contributes to the atherogenic disease processes and elevates levels of biomarkers of inflammation. Besides, this chronic

Table 4. Relation between CHD risk factors and CA-125 level among controls.

| Demographic and risk factors | N (n = 3531) | CA-125, mean ± SD (U/ml) | P-value |
|-----------------------------|-------------|--------------------------|--------|
| Age                         |             |                          |        |
| < 60                        | 319         | 6.90 ± 8.34              | 0.001  |
| ≥ 60                        | 1703        | 6.25 ± 6.99              |        |
| ≥ 70                        | 1509        | 7.04 ± 6.64              |        |
| Gender                      |             |                          |        |
| Male                        | 1853        | 6.96 ± 7.69              | 0.01   |
| Female                      | 1678        | 6.30 ± 6.11              |        |
| BMI                         |             |                          |        |
| ≤ 23.9                      | 1605        | 6.55 ± 7.00              | 0.07   |
| 24-                         | 1387        | 6.65 ± 7.29              |        |
| ≥ 28                        | 464         | 7.03 ± 6.20              |        |
| Medication history          |             |                          |        |
| Antibiotics                 |             |                          |        |
| Yes                         | 177         | 6.74 ± 6.96              | 0.93   |
| No                          | 3354        | 6.64 ± 6.99              |        |
| Anticoagulant               |             |                          |        |
| Yes                         | 359         | 7.10 ± 6.21              | 0.07   |
| No                          | 3172        | 6.60 ± 7.07              |        |
| Anti-hypertensive medication|             |                          | 0.31   |
| Yes                         | 965         | 6.68 ± 6.00              |        |
| No                          | 2566        | 6.63 ± 7.33              |        |
| Hypoglycemic medication     |             |                          | 0.03   |
| Yes                         | 346         | 7.17 ± 6.08              |        |
| No                          | 3185        | 6.59 ± 7.08              |        |
| Smoking status              |             |                          |        |
| Current                     | 693         | 6.69 ± 7.54              | 0.04   |
| Former                      | 415         | 7.62 ± 9.84              |        |
| Never                       | 2405        | 6.47 ± 6.19              |        |
| Drinking status             |             |                          | 0.11   |
| Current                     | 788         | 6.80 ± 7.24              |        |
| Former                      | 159         | 8.37 ± 13.75             |        |
| Never                       | 2583        | 6.49 ± 6.24              |        |
| Disease History             |             |                          |        |
| Hypertension                |             |                          | 0.001  |
| Yes                         | 1919        | 6.36 ± 6.44              |        |
| No                          | 1612        | 6.99 ± 7.57              |        |
| Dyslipidemia                |             |                          | > 0.05 |
| Yes                         | 1932        | 6.84 ± 7.41              |        |
| No                          | 1599        | 6.40 ± 6.44              |        |
| Diabetes mellitus           |             |                          | < 0.001|
| Yes                         | 664         | 7.41 ± 6.26              |        |
| No                          | 2867        | 6.47 ± 7.14              |        |

doi: 10.1371/journal.pone.0081328.t004
state of inflammation might be directly related to subsequent elevated risk for cardiovascular diseases and has detrimental effects on the metabolism and function of innate immune cells [47,48]. The plausibility is supported by our observation that among controls smokers tended to have higher level of serum CA-125 than nonsmokers.

An inverse correlation between CA-125 level and metabolic syndrome was recently reported in a study including 12,196 healthy Korean women [49]. Similar results have been also found in the present study. For example, controls with hypertension had significantly lower serum CA-125 level than those without hypertension. While conflicting findings showed that serum CA-125 levels were associated with lower risks of CHD in patients with dyslipidemia and diabetes mellitus after adjustment with confounding factors. That may be due to the different doses and/or the duration of the medicines they taken. However, the precise mechanisms should be investigated in future prospective studies.

In terms of limitations, the current case-control design limits the causal interpretation of the relationship between serum CA-125 level and the risk of coronary heart disease because the blood samples were collected from subjects having CHD events. Another limitation is that some CHD cases took multiple medications, which acted as a confounding factor when we analyzed the relationship between CA-125 level and CHD risk by subgroups. Thus, such findings need to be validated by future large prospective investigations. Furthermore, the role of unmeasured or residual confounding could not be ignored although we have adjusted for a wide range of CHD risk factors. Nevertheless, this is the first study to examine the association between serum CA-125 level and the risk of CHD in a large Chinese older population. Secondly, the sample size is considerable, which allows us to investigate the association between increased CA-125 level and CHD risk.

Conclusions

In summary, our findings suggested that higher serum CA-125 level might be associated with a significantly increased risk of CHD in Chinese older population. Future prospective studies should be motivated by this finding to explore the precise mechanisms.

Supporting Information

Table S1. The association between CA-125 level and CHD with nonfatal MI in Chinese older population.

Table S2. The association between CA-125 level and CHD without nonfatal MI in Chinese older population.

Acknowledgements

We thank all study participants and staffs of the Health Examination Center of the Dongfeng Central Hospital and the Medical Insurance Center of DMC for their generous help. We also thank the interviewers from the retirement management office of DMC and from Tongji Medical College, HUST.

Author Contributions

Conceived and designed the experiments: FBH TCW HDY. Performed the experiments: JZ PY XLL MJL XWM JY SW. Analyzed the data: SW MAH XRL. Wrote the manuscript: XRL.

References

1. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S (1993) CA-125 in gynecological pathology—a review. Eur J Obstet Gynecol Reprod Biol 49: 115-124. doi:10.1016/0028-2243(93)90135-Y. PubMed: 8365505.
2. Sikaris KA (2011) CA125—a test with a change of heart. Heart Lung Circ 20: 634-640. doi:10.1016/j.hlc.2010.08.001. PubMed: 20822954.
3. Saygili U, Guclu S, Uslu T, Erten O, Dogan E (2002) The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer 12: 438-442. doi:10.1046/j.1525-1438.2002.00171.x. PubMed: 12366859.
4. Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y et al. (2002) Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85: 108-113. doi:10.1006/gyno.2001.6575. PubMed: 11925128.
5. Koursi NT, Zacharos ID, Kontogianni DD, Goraniotou GS, Sfikad MD et al. (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7: 199-203. doi:10.1016/j.ejheart.2004.07.015. PubMed: 15701467.
6. D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G et al. (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41: 1805-1811. doi:10.1016/S0735-1097(03)00311-S. PubMed: 12767668.
7. Varol E, Ozaydin M, Dogan A, Kosar F (2005) Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7: 840-843. doi:10.1016/j.ejheart.2004.12.006. PubMed: 15918923.
8. De Gennaro L, Brunetti ND, Bungaro R, Montrone D, Cuculo A et al. (2009) Carbohydrate antigen-125: additional accuracy in identifying patients at risk of acute heart failure in acute coronary syndrome. Coron Artery Dis 20: 274-280. doi:10.1097/MCA.0b013e3282329d82. PubMed: 19440066.
9. Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C et al. (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24: 172-175. doi:10.1159/000074425. PubMed: 14654710.
10. Varol E, Ozaydin M, Altinbas A, Aslan SM, Dogan A et al. (2007) Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. Heart Vessels 22: 30-33. doi:10.1007/s00380-006-0938-9. PubMed: 17285443.
11. Ragni T, Da Col U, Di Manici G, Di Bella I, Di Lazzaro D et al. (2003) A case of pseudoaneurysm of the left ventricular lateral wall. Diagnosis and surgical treatment. Ital Heart J Suppl 4: 340-343. PubMed: 12784770.
12. Yanada M, Shimada J, Ito K, Terauchi K, Shimomura M (2007) Cardiac angiosarcoma with diagnostic difficulty. Kyobu Geka 60: 1148-1151. PubMed: 18078079.
13. Chelbi F, Hamzaoui A, Kacem M, Hammami S, Mahjoub S (2002) Increase of CA-125 in pericardial tamponade. Presse Med 31: 340-343. PubMed: 12373390.
14. Rostoff P, Mrozczek-Czereckia D, Piwowarska W (2008) Elevated CA-125 level in acute heart failure due to Toxoplasma gondii perimyocarditis. Int J Cardiol 130: e114-e116. doi:10.1016/j.ijcard.2007.07.018. PubMed: 17689762.
15. De Gennaro L, Brunetti ND, Montrone D, De Rosa F, Cuculo A et al. (2012) Inflammatory activation and carbohydrate antigen-125 levels in...
subjects with atrial fibrillation. Eur J Clin Invest 42: 371-375. doi: 10.1111/j.1365-2362.2011.05269.x. PubMed: 21913017.

16. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S et al. (2010) Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 121: e46-e209. doi:10.1161/CIRCULATIONAHA.109.192667. PubMed: 20019324.

17. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD et al. (2011) Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 125: e2-e202. doi:10.1161/CIR.0b013e3182138a05. PubMed: 21719539.

18. Pandey C, Marchioli R (2006) Progress of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442. doi: 10.1371/journal.pmed.0030442. PubMed: 17132052.

19. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340: 115-125. doi:10.1056/NEJM199901133400207. PubMed: 9887164.

20. Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22: 361-403. doi:10.1146/annurev.immunol.22.110202.135704. PubMed: 15032582.

21. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 688-697. doi:10.1038/35013233. PubMed: 12099600.

22. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES et al. (2003) Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 42: 3-7. doi:10.1093/rheumatology/keg022. PubMed: 17702769.

23. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM et al. (2005) Autoimmune and inflammatory burden of disease from 2002 to 2030. PLoS Med 3: e442. doi: 10.1371/journal.pmed.0030442. PubMed: 17132052.

24. sink disease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol10;60(Columns): e44-e164.

25. Wang F, Zhu J, Yao P, Li X, He M et al. (2013) Cohort profile: The Dongfeng-Tongji cohort study of retired workers. Int J Epidemiol, 42: 731-40. PubMed: 22531126.

26. El-Mesallamy HO, Hamdy NM, Salman TM, Ibrahim SM et al. (2012) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody CA125. Int J Gynecol Pathol 2: 227-285. doi:10.1097/00004347-198303000-00005. PubMed: 6193631.

27. Sugishita H, Imagawa H, Kowachi K, Takano S, Tsunoaka N et al. (2005) Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis. Jpn J Thorac Cardiovasc Surg 53: 486-489. doi: 10.1007/s11748-005-0092-9. PubMed: 16200899.

28. Varol E, Yücel H, Arslan A, Ozyazdin M, Erdogan D et al. (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40: 309-315. doi:10.5543/tkda.2012.87894. PubMed: 22951846.

29. Antunini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R et al. (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128: 406-412. doi: 10.1016/j.ijcard.2007.05.039. PubMed: 17662495.

30. Duman C, Erkan E, Tengiz I, Bozdemir H, Erkan HE et al. (2003) Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardio 100: 7-10. doi: 10.1159/000072385. PubMed: 12975539.

31. Yalta K, Yilmaz A, Turgut OO, Ersemerc T, Yilmaz MB et al. (2006) Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction. Adv Ther 23: 1052-1059. doi:10.1007/BF02950225. PubMed: 17276972.

32. Kabawat SE, Bast RC Jr, Bhan AK, Weich WR, Knapp RC et al. (1993) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody CA125. Int J Gynecol Pathol 2: 275-285. doi:10.1097/00004347-198303000-00005. PubMed: 6193631.

33. Kabawat SE, Bast RC Jr, Bhan AK, Weich WR, Knapp RC et al. (1993) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody CA125. Int J Gynecol Pathol 2: 275-285. doi:10.1097/00004347-198303000-00005. PubMed: 6193631.

34. Sugishita H, Imagawa H, Kowachi K, Takano S, Tsunoaka N et al. (2005) Normalization of cancer antigen 125 after mitral valve replacement in a patient with congestive heart failure due to mitral valve endocarditis. Jpn J Thorac Cardiovasc Surg 53: 486-489. doi: 10.1007/s11748-005-0092-9. PubMed: 16200899.

35. Varol E, Yücel H, Arslan A, Ozyazdin M, Erdogan D et al. (2012) Elevated carbohydrate antigen 125 levels in patients with aortic stenosis: relation to clinical severity and echocardiographic parameters. Turk Kardiyol Dern Ars 40: 309-315. doi:10.5543/tkda.2012.87894. PubMed: 22951846.

36. Antunini-Canterin F, Popescu BA, Popescu AC, Beladan CC, Korcova R et al. (2008) Heart failure in patients with aortic stenosis: clinical and prognostic significance of carbohydrate antigen 125 and brain natriuretic peptide measurement. Int J Cardiol 128: 406-412. doi: 10.1016/j.ijcard.2007.05.039. PubMed: 17662495.

37. Duman C, Erkan E, Tengiz I, Bozdemir H, Erkan HE et al. (2003) Elevated serum CA 125 levels in mitral stenotic patients with heart failure. Cardio 100: 7-10. doi: 10.1159/000072385. PubMed: 12975539.